Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analysts Endorse Ranbaxy-Pfizer Deal On Lipitor

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Analysts have backed the settlement deal between Ranbaxy Laboratories and Pfizer on the latter's blockbuster cholesterol-lowering drug Lipitor (atorvastatin) calling it a "very positive" development for the Indian drug maker

You may also be interested in...



Ranbaxy’s First-To-File ANDAs At Risk In FDA Data Integrity Probe

Several first-to-file ANDAs are on the line for Ranbaxy as it tries to resolve data integrity issues at its Paonta Sahib facility with U.S. FDA

Ranbaxy’s First-To-File ANDAs At Risk In FDA Data Integrity Probe

Several first-to-file ANDAs are on the line for Ranbaxy as it tries to resolve data integrity issues at its Paonta Sahib facility with U.S. FDA

Ranbaxy Sees Light At The End Of DoJ Investigation Tunnel - CEO Interview

MUMBAI - India's largest drug maker Ranbaxy is confident that the U.S. Department of Justice will soon withdraw its motion filed against the company, Ranbaxy CEO Malvinder Singh said in an interview with PharmAsia News

Related Content

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel